FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376642154> ?p ?o ?g. }

• W4376642154 endingPage "228" @default.
• W4376642154 startingPage "220" @default.
• W4376642154 abstract "Health status outcomes, including symptoms, function, and quality of life, are worse for Black compared with White patients with heart failure. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce cardiovascular mortality and improve health status in patients with heart failure, but whether the health status benefit of SGLT2is is similar across races is not established. The objective of this study was to compare the treatment effect of SGLT2is (versus placebo) on health status for Black compared with White patients with heart failure.We combined patient-level data from 3 randomized clinical trials of SGLT2is: DEFINE-HF (Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure; n=263), PRESERVED-HF (Dapagliflozin in Preserved Ejection Fraction Heart Failure; n=324), and CHIEF-HF (A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure; n=448). These 3 United States-based trials enrolled a substantial proportion of Black patients, and each used the Kansas City Cardiomyopathy Questionnaire (KCCQ) to measure health status at baseline and after 12 weeks of treatment. Among 1035 total participants, selecting self-identified Black and White patients with complete information yielded a final analytic cohort of 935 patients. The primary endpoint was KCCQ Clinical Summary score. Twelve-week change in KCCQ with SGLT2is versus placebo was compared between Black and White patients by testing the interaction between race and treatment using multivariable linear regression models adjusted for trial, baseline KCCQ (as a restricted cubic spline), race, and treatment. The data that support the findings of this study are available from the corresponding author upon reasonable request.Among 935 participants, 236 (25%) self-identified as Black, and 469 (50.2%) were treated with an SGLT2i. Treatment with an SGLT2i, compared with placebo, resulted in KCCQ Clinical Summary score improvements at 12 weeks of +4.0 points (95% CI, 1.7-6.3; P=0.0007) in White patients and +4.7 points (95% CI, 0.7-8.7; P=0.02) in Black patients, with no significant interaction by race and treatment (P=0.76). Other KCCQ scales showed similar results.Treatment with an SGLT2i resulted in consistent and significant improvements in health status for both Black and White patients with heart failure." @default.
• W4376642154 created "2023-05-17" @default.
• W4376642154 creator A5001655356 @default.
• W4376642154 creator A5015021993 @default.
• W4376642154 creator A5016883684 @default.
• W4376642154 creator A5022314919 @default.
• W4376642154 creator A5028502868 @default.
• W4376642154 creator A5039800294 @default.
• W4376642154 creator A5042843111 @default.
• W4376642154 creator A5043064522 @default.
• W4376642154 creator A5044527590 @default.
• W4376642154 creator A5047622393 @default.
• W4376642154 creator A5052533254 @default.
• W4376642154 creator A5054890754 @default.
• W4376642154 creator A5091258123 @default.
• W4376642154 date "2023-07-18" @default.
• W4376642154 modified "2023-10-17" @default.
• W4376642154 title "Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium–Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials" @default.
• W4376642154 cites W1603091860 @default.
• W4376642154 cites W1939947548 @default.
• W4376642154 cites W2009235544 @default.
• W4376642154 cites W2010579338 @default.
• W4376642154 cites W2044591445 @default.
• W4376642154 cites W2062608369 @default.
• W4376642154 cites W2073944740 @default.
• W4376642154 cites W2083650930 @default.
• W4376642154 cites W2126617656 @default.
• W4376642154 cites W2134697036 @default.
• W4376642154 cites W2140023412 @default.
• W4376642154 cites W2255756224 @default.
• W4376642154 cites W2303436247 @default.
• W4376642154 cites W2572452509 @default.
• W4376642154 cites W2729581192 @default.
• W4376642154 cites W2766278264 @default.
• W4376642154 cites W2766542337 @default.
• W4376642154 cites W2782942098 @default.
• W4376642154 cites W2805504067 @default.
• W4376642154 cites W2942881797 @default.
• W4376642154 cites W2974260792 @default.
• W4376642154 cites W2976185156 @default.
• W4376642154 cites W2989060738 @default.
• W4376642154 cites W3003299879 @default.
• W4376642154 cites W3049044868 @default.
• W4376642154 cites W3081830235 @default.
• W4376642154 cites W3082758064 @default.
• W4376642154 cites W3102378350 @default.
• W4376642154 cites W3102518094 @default.
• W4376642154 cites W3153561131 @default.
• W4376642154 cites W3169938601 @default.
• W4376642154 cites W3193297191 @default.
• W4376642154 cites W3193598686 @default.
• W4376642154 cites W3201992132 @default.
• W4376642154 cites W4200592623 @default.
• W4376642154 cites W4214512384 @default.
• W4376642154 cites W4225396975 @default.
• W4376642154 cites W4240587969 @default.
• W4376642154 cites W4283218619 @default.
• W4376642154 cites W4289262214 @default.
• W4376642154 cites W4293354639 @default.
• W4376642154 cites W4311441791 @default.
• W4376642154 doi "https://doi.org/10.1161/circulationaha.122.063263" @default.
• W4376642154 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37191040" @default.
• W4376642154 hasPublicationYear "2023" @default.
• W4376642154 type Work @default.
• W4376642154 citedByCount "0" @default.
• W4376642154 crossrefType "journal-article" @default.
• W4376642154 hasAuthorship W4376642154A5001655356 @default.
• W4376642154 hasAuthorship W4376642154A5015021993 @default.
• W4376642154 hasAuthorship W4376642154A5016883684 @default.
• W4376642154 hasAuthorship W4376642154A5022314919 @default.
• W4376642154 hasAuthorship W4376642154A5028502868 @default.
• W4376642154 hasAuthorship W4376642154A5039800294 @default.
• W4376642154 hasAuthorship W4376642154A5042843111 @default.
• W4376642154 hasAuthorship W4376642154A5043064522 @default.
• W4376642154 hasAuthorship W4376642154A5044527590 @default.
• W4376642154 hasAuthorship W4376642154A5047622393 @default.
• W4376642154 hasAuthorship W4376642154A5052533254 @default.
• W4376642154 hasAuthorship W4376642154A5054890754 @default.
• W4376642154 hasAuthorship W4376642154A5091258123 @default.
• W4376642154 hasBestOaLocation W43766421541 @default.
• W4376642154 hasConcept C126322002 @default.
• W4376642154 hasConcept C134018914 @default.
• W4376642154 hasConcept C142724271 @default.
• W4376642154 hasConcept C159110408 @default.
• W4376642154 hasConcept C164705383 @default.
• W4376642154 hasConcept C203092338 @default.
• W4376642154 hasConcept C204787440 @default.
• W4376642154 hasConcept C27081682 @default.
• W4376642154 hasConcept C2777180221 @default.
• W4376642154 hasConcept C2777451236 @default.
• W4376642154 hasConcept C2778198053 @default.
• W4376642154 hasConcept C2779951463 @default.
• W4376642154 hasConcept C535046627 @default.
• W4376642154 hasConcept C555293320 @default.
• W4376642154 hasConcept C71924100 @default.
• W4376642154 hasConcept C78085059 @default.
• W4376642154 hasConceptScore W4376642154C126322002 @default.
• W4376642154 hasConceptScore W4376642154C134018914 @default.

• next